Pamplona, Spain – Palobiofarma S.L. is pleased to announce that the FDA and the EMA have granted Orphan Drug Designation to our novel therapeutic candidate, PBF-999, for the treatment of Prader-Willi Syndrome (PWS). These designations represent a significant milestone in our commitment to...